Mizuho Securities Raises Price Target Following salesforce.com (CRM) 3Q Beat

salesforce.com (CRM) Reports Record Revenue; Roth Capital Reiterates Buy

November 19, 2015 11:35 AM EST

Roth Capital reiterated a Buy rating on salesforce.com (NYSE: CRM), and raised the price target to $93.00 (from $80.00), following the company's 3Q earnings report. Revenues grew 24.0% y/y to a record $1.712B, and drove pro forma EPS of $0.21. These results beat Roth's estimates of $1.698B... More

Salesforce.com's (CRM) Q4 Guidance Seen as Conservative at Deutsche Bank

November 19, 2015 10:27 AM EST

Deutsche Bank maintained a Buy rating on salesforce.com (NYSE: CRM) with a price target of $90. Analyst Karl Keirstead noted the company's solid Q3 print and said Q4 guidance looks conservative.

"Salesforce posted a modest 3QF16 beat that in our view should be good enough for the stock. The quarter was highlighted by DR growth of 30% in c/c (the 6th consecutive quarter in the28%-32% growth range and above... More

Nomura Securities Reiterates Buy on salesforce.com (CRM) Following Solid 3Q Results

November 19, 2015 9:14 AM EST

Nomura Securities reiterated a Buy rating and $90.00 price target on salesforce.com (NYSE: CRM) following the company's 3Q earnings report. Salesforce reported billings of $1.52bn, up 21% yoy and 2% above the consensus estimate of $1.49bn. Additionally, Salesforce posted revenues of $1.71bn (+24% yoy), above consensus of $1.70bn.... More

Canaccord Genuity Says salesforce.com (CRM) is 'Structural Buy'; Raises Price Target to $95

November 19, 2015 9:07 AM EST

Canaccord Genuity reiterated a Buy rating on salesforce.com (NYSE: CRM), and raised the price target to $95.00 (from $85.00), following the company's 3Q earnings report. CRM reported revenue and non-GAAP EPS of $1.71B and $0.21, which were respectively $12M and $0.02 ahead of Cannaccord's estimates.

Analyst Richard... More

salesforce.com (CRM) Reports Solid 3Q Across the Board; Needham & Company Raises Price Target to $90

November 19, 2015 8:17 AM EST

Needham & Company reiterated a Buy rating on salesforce.com (NYSE: CRM), and raised the price target to $90.00 (from $85.00), following the company's 3Q earnings report. CRM reported solid results across the board. The quarter was highlighted by 21% billings growth, which suggests healthy fundamentals, the strength of Salesforce's... More

Wall St. edges down; healthcare sinks and Intel climbs

November 19, 2015 7:15 AM EST

By Noel Randewich

(Reuters) - Wall Street ended a little lower on Thursday as falling healthcare stocks offset gains in Intel and other technology names while investors eyed an expected rate hike in December.

A profit warning by UnitedHealth (NYSE: UNH) led to a 5.65 percent drop in its stock, making the health insurer the biggest drag on the Dow Jones industrial average and the S&P 500. It also sent the shares of competitors Anthem (NYSE: ANTM) and Aetna (NYSE:... More

FBR Capital Maintains Bullish View on salesforce (CRM) Following Strong Q3

November 19, 2015 6:55 AM EST

salesforce.com (NYSE: CRM) revenue of $1.71B beat consensus of $1.70B. Billings of $1.52B beat consensus of $1.49B and grew 21% YOY. Billings of $1.52 billion beat consensus of $1.49 billion and grew 21% year over year. Operating margin of 13.3% beat consensus of 12.1%. Pro forma EPS of $0.21 beat consensus of $0.19.

For F4Q, the... More

After-Hours Movers 11/18: (KBIO) (VTAE) (GMCR) Higher; (SUNE) (GLBL) (VSLR) Lower (more...)

November 18, 2015 6:00 PM EST

KaloBios Pharma (NASDAQ: KBIO) 611% HIGHER; Martin Shkreli disclosed buying 1,211,115 shares from November 16, 2015-November 17, 2015. Prices paid ranged from $0.61-$2.43.

Vitae Pharmaceuticals (NASDAQ: VTAE) 38.7% HIGHER; reported positive top-line results from the healthy human volunteer part of the multiple ascending dose Phase 1 clinical trial of VTP-43742. VTP-43742 is Vitae's wholly owned, orally active RORt inhibitor with the potential to transform the treatment of multiple autoimmune disorders, including psoriasis, through the potent inhibition of IL-17 secretion from Th17 cells and blocking the... More

Market Wrap: Fed Hints at Dec. Hike; China Trims Treasury Holdings; Housing Starts Lags in Oct.; Apple Gains on Goldman Call

November 18, 2015 5:26 PM EST

Market wrap for November 18th

End of the Day: S&P 500 up 33.1 to 2,083.58; Dow Jones up 247.7 to 17,737.16; Nasdaq up 89.2 to 5,075.20

Market Brief: China lowered its U.S. Treasury holdings to $1.258 trillion, which was the lowest level seen in seven months, while Japan cut its stake to $1.17 trillion, the lowest in nearly two years.

The FOMC indicated that a rate hike might be coming in December, according to the minutes from its latest meeting.

Apple moved higher following... More

salesforce.com (CRM) Tops Q3 EPS by 2c; Boosts FY16 Outlook

November 18, 2015 4:06 PM EST

salesforce.com (NYSE: CRM) reported Q3 EPS of $0.21, $0.02 better than the analyst estimate of $0.19. Revenue for the quarter came in at $1.71 billion versus the consensus estimate of $1.7 billion.

salesforce.com sees FY2016 EPS of $0.74 - $0.75, versus the consensus of $0.73. salesforce.com sees FY2016 revenue... More

Trading Radar for 11/18: Target (TGT), salesforce (CRM), Staples (SPLS), Lowe's (LOW), Hillenbrand (HI) Report

November 17, 2015 3:54 PM EST

The Trading Radar highlights key earnings and economic announcements for the next trading session:

Before Markets Open:
Economics:
7:00am EST

MBA Mortgage Index - no Street consensus

8:30am EST

Housing Starts - Street sees 1.173MBuilding Permits - Street sees 1.137M

Earnings:

Aramark Services (NYSE: ARMK) - consensus EPS $0.39
Daqo... More